Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 13/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 12/20 | 0.51 |
| ▸ | CDK2 | P24941 | 12/20 | 0.51 |
| ▸ | CDC7 | O00311 | 12/20 | 0.51 |
| ▸ | DBF4 | Q9UBU7 | 12/20 | 0.51 |
| ▸ | USP19 | O94966 | 1/20 | 0.34 |
| ▸ | CYP46A1 | Q9Y6A2 | 5/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10238474 | 0.82 | CCNE1 (0.48) | ROCK1CCNE1CDK2CDC7DBF4 | |
| SCHEMBL612014 | 0.80 | ROCK1 (0.61) | ROCK1CCNE1CDK2CDC7DBF4 | |
| SCHEMBL614070 | 0.80 | ROCK1 (0.56) | ROCK1CCNE1CDK2CDC7DBF4 | |
| SCHEMBL612018 | 0.80 | ROCK1 (0.56) | ROCK1CCNE1CDK2CDC7DBF4 | |
| SCHEMBL613682 | 0.79 | ROCK1 (0.59) | ROCK1CCNE1CDK2CDC7DBF4 | |
| SCHEMBL614047 | 0.78 | ROCK1 (0.58) | ROCK1CCNE1CDK2CDC7DBF4 | |
| SCHEMBL613977 | 0.78 | ROCK1 (0.65) | ROCK1CCNE1CDK2CDC7DBF4 | |
| SCHEMBL612136 | 0.77 | ROCK1 (0.70) | ROCK1CCNE1CDK2CDC7DBF4 | |
| SCHEMBL614576 | 0.77 | ROCK1 (0.66) | ROCK1CCNE1CDK2CDC7DBF4 | |
| SCHEMBL613283 | 0.76 | ROCK1 (0.62) | ROCK1CCNE1CDK2CDC7DBF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | CDC7, CDK7, DTYMK | ROCK1 2609/4885CCNE1 158/4885CDK2 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.